U.S. Nuclear Imaging Devices Market Size, Share & Forecast 2026–2032

ID: MR-11736 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Nuclear Imaging Devices Market
  • ✓Market Size 2024: USD 1.42 billion
  • ✓Market Size 2032: USD 2.30 billion
  • ✓CAGR: 6.2%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
PSMA therapy pulls PET capacity: PSMA-targeted therapy is pulling PET capacity into oncology networks. Novartis's Pluvicto, FDA-approved in March 2022, requires PSMA-positive confirmation through an approved PET agent before each cycle. Community oncology groups buy dedicated PET/CT systems instead of referring to academic departments.
FINDING 02
Tracer supply, not scanners: The common view holds that anti-amyloid antibodies will drive scanner demand. The binding constraint is F-18 tracer supply from regional cyclotron networks, not PET hardware. Hospitals without tracer access will lose Leqembi and Kisunla patients to competitors.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure tracer contracts now: Hospital procurement directors and PET/CT investors should lock multi-year F-18 fluorodeoxyglucose and amyloid tracer supply agreements with regional cyclotron operators before the fourth quarter of 2026. Scanner purchases without tracer access leave capacity idle and forfeit anti-amyloid treatment volume.

Nuclear Imaging Devices in the United States: Market Overview

The United States accounted for roughly USD 1.42 billion of nuclear imaging device revenue in 2024, with PET/CT and SPECT/CT systems representing the bulk of spending. The installed base is concentrated in hospitals and freestanding outpatient imaging centres, which operate under Medicare Part B reimbursement set through the CMS Physician Fee Schedule and the Hospital Outpatient Prospective Payment System. Private suppliers, principally GE HealthCare, Siemens Healthineers and Philips, have led product innovation.

Government has been the dominant force in demand shaping and market access. The Radiation Control for Health and Safety Act of 1968 gave the FDA's Center for Devices and Radiological Health authority over electronic product radiation, while the Atomic Energy Act places radioactive material under the Nuclear Regulatory Commission, with Agreement States licensing most clinics. The Veterans Affairs system, operating under the VA MISSION Act of 2018, remains a major federal purchaser, while private leadership dominates scanner design and software.

Policy-Driven Growth in U.S. Nuclear Imaging

Three mechanisms drive demand. First, the 21st Century Cures Act of 2016 authorised USD 1.8 billion for the Cancer Moonshot over seven fiscal years, funding oncology research that depends on PET staging. Second, CMS removed prior coverage restrictions on amyloid PET under National Coverage Determination 220.6.20 in October 2023, so anti-amyloid antibodies such as Leqembi and Kisunla require confirmatory scans. Third, FDA approval of Pluvicto in March 2022 made PSMA PET a prerequisite for therapy.

Mechanism matters more than headline funding. Reimbursed PET procedures under CPT codes 78811 through 78816 convert clinical eligibility directly into scanner utilisation, and hospitals justify capital purchases against per-scan Medicare revenue. Cures Act money flows through research grants, so its effect is indirect, whereas CMS coverage decisions and FDA label expansions translate immediately into billable procedures and purchase orders.

Regulatory Barriers and Compliance Costs

FDA premarket clearance is the first barrier. Scanners are reviewed under 21 CFR 892.1200 for emission computed tomography systems, usually through 510(k) clearance with a MDUFA performance goal of 90 FDA days, but total review time frequently exceeds six months after additional information requests. Manufacturers must also comply with the Quality Management System Regulation, effective 2 February 2026, which aligns 21 CFR Part 820 with ISO 13485:2016, and Section 524B of the FD&C Act requires cybersecurity documentation for connected systems.

Radioactive material controls add a second layer. The NRC licenses byproduct material under 10 CFR Part 35, and Agreement States such as California and Texas issue facility licences, with radiation safety officer approval and shielding design review adding months to site commissioning. Shielding for a new PET/CT suite can cost several hundred thousand USD, and diagnostic X-ray components of hybrid units must meet the radiation performance standard in 21 CFR 1020.30.

Policy-Created Opportunities in U.S. Nuclear Imaging

Amyloid PET capacity in community hospitals represents the first opportunity. Following the removal of CMS coverage restrictions under NCD 220.6.20, and given the FDA labelling requirement that anti-amyloid therapies be prescribed only after confirmation of amyloid pathology, hospitals without PET access face referral losses. Vendors offering compact PET/CT systems with simplified installation requirements can capture this demand directly.

Federal procurement offers the second opportunity. The VA MISSION Act of 2018 directs veterans toward community care while the Veterans Affairs Office of Acquisition, Logistics, and Construction continues to buy imaging systems through national contracts. The DOE Isotope Program supports domestic production of medical isotopes, and vendors aligned with NorthStar Medical Radioisotopes and SHINE Technologies can position for supply-chain resilience demand.

Market at a Glance

MetricValue
Market Size 2024USD 1.42 billion
Market Size 2032USD 2.30 billion
Growth Rate (CAGR)6.2%
Most Critical Decision FactorReimbursed procedure volume per scanner under CMS payment schedules
Largest RegionSouth Region (U.S. Census Bureau)
Competitive StructureOligopolistic, led by three global OEMs

Leading Market Participants

  • GE HealthCare
  • Siemens Healthineers
  • Philips Healthcare
  • Canon Medical Systems USA
  • United Imaging Healthcare
  • Spectrum Dynamics Medical
  • Mediso USA
  • MILabs
  • Kromek
  • Digirad

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act, whose device provisions govern PET and SPECT scanners, and the Atomic Energy Act of 1954, which governs the radioactive tracers they image. FDA's Center for Devices and Radiological Health administers device clearance, while the Nuclear Regulatory Commission and Agreement States license byproduct material under 10 CFR Part 35. Key compliance requirements include 510(k) clearance, Section 524B cybersecurity plans, and QMSR alignment effective 2 February 2026.

Upcoming changes have fixed dates. MDUFA VI negotiations must conclude with FDA transmitting recommendations to Congress by 15 January 2027, ahead of program expiry on 30 September 2027. Compared with regional peers, the U.S. framework reaches market faster than the EU Medical Device Regulation (EU) 2017/745, where notified body capacity lengthens certification, and it is more fragmented than Health Canada's national licensing under SOR/98-282.

Long-Term Policy Outlook for U.S. Nuclear Imaging

By 2032, CMS payment policy will determine procedure volume more than device specifications. The annual Medicare Physician Fee Schedule and OPPS rules will set reimbursement for PET procedures and shape hospital purchasing cycles, while further CMS coverage reviews for neurology and oncology tracers will expand reimbursed indications. Site-of-service policy will move more PET procedures into ambulatory settings.

Regulatory reform will tighten compliance costs. NRC rulemaking to revise 10 CFR Part 35 is expected to alter training and authorised-user requirements, while MDUFA VI will set FDA review performance goals for the post-2027 period. Market growth will track the 6.2% CAGR only if tracer supply chains, especially cyclotron-produced F-18 and domestic molybdenum-99, remain resilient.

Frequently Asked Questions

Most new PET/CT systems enter the market through 510(k) clearance under 21 CFR 892.1200. The FDA's Center for Devices and Radiological Health reviews the submission against a predicate device.
Radiopharmaceuticals are approved as drugs by FDA's Center for Drug Evaluation and Research under the FD&C Act. Medical use of the radioactive material is licensed by the NRC or an Agreement State under 10 CFR Part 35.
The Quality Management System Regulation, effective 2 February 2026, replaces 21 CFR Part 820 with requirements aligned to ISO 13485:2016. Manufacturers must update design controls and supplier management procedures before that date.
CMS covers amyloid PET under NCD 220.6.20 following its October 2023 decision. That decision removed the prior restrictions, including the registry participation requirement.
The current MDUFA V authority expires on 30 September 2027. FDA must transmit its MDUFA VI recommendations to Congress by 15 January 2027.

Market Segmentation

By Device Type
  • PET/CT Systems
  • SPECT/CT Systems
  • Standalone PET Scanners
  • Gamma Cameras
  • Total-Body PET Systems
By End User
  • Hospitals
  • Ambulatory Imaging Centres
  • Academic Medical Centres
  • Veterans Affairs Facilities
  • Oncology Treatment Centres

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Nuclear Imaging Devices - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Device Type Insights
4.1 PET/CT Systems
4.2 SPECT/CT Systems
4.3 Standalone PET Scanners
4.4 Gamma Cameras
4.5 Others
Chapter 05 End User Insights
5.1 Hospitals
5.2 Ambulatory Imaging Centres
5.3 Academic Medical Centres
5.4 Veterans Affairs Facilities
5.5 Others
Chapter 06 Competitive Landscape
6.1 Market Players
6.2 Leading Market Participants
6.2.1 GE HealthCare
6.2.2 Siemens Healthineers
6.2.3 Philips Healthcare
6.2.4 Canon Medical Systems USA
6.2.5 United Imaging Healthcare
6.2.6 Spectrum Dynamics Medical
6.2.7 Mediso USA
6.2.8 MILabs
6.2.9 Kromek
6.2.10 Digirad
6.3 Regulatory Environment
6.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.